ReviewExpert opinion on biological therapy2014
Self-renewal and cell lineage differentiation strategies in human embryonic stem cells and induced pluripotent stem cells.
Review in Expert opinion on biological therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Metabolic patterns predispose human pluripotent stem cells to spatial organization of cell fate.Frontiers in cell and developmental biology · 2025Article
- The Kleisin Subunits of Cohesin are Involved in the Fate Determination of Embryonic Stem Cells.Molecules and cells · 2022Article
- Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.The CRISPR journal · 2022Review
- Feasibility and application of polygenic score analysis to the morphology of human-induced pluripotent stem cells.Molecular genetics and genomics : MGG · 2022Article
- Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic.NPJ Regenerative medicine · 2021Review
- The Effects of Bilirubin and Lumirubin on the Differentiation of Human Pluripotent Cell-Derived Neural Stem Cells.Antioxidants (Basel, Switzerland) · 2021Article
- Differences and similarities between cancer and somatic stem cells: therapeutic implications.Stem cell research & therapy · 2020Review
- Quantification of the morphological characteristics of hESC colonies.Scientific reports · 2019Article
- Stem cells: past, present, and future.Stem cell research & therapy · 2019Review
- iPSCs-based generation of vascular cells: reprogramming approaches and applications.Cellular and molecular life sciences : CMLS · 2018Review
- Anti-Cancer Phytometabolites Targeting Cancer Stem Cells.Current genomics · 2017Review
- Increased activity of TNAP compensates for reduced adenosine production and promotes ectopic calcification in the genetic disease ACDC.Science signaling · 2016Article
- Epigenesis and plasticity of mouse trophoblast stem cells.Cellular and molecular life sciences : CMLS · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionSince the initial discoveries of human embryonic and induced pluripotent stem cells, many strategies have been developed to utilize the potential of these cells for translational research and disease modeling. The success of these aims and the development of future applications in this area will depend on the ability to generate high-quality and large numbers of differentiated cell types that genetically, epigenetically, and functionally mimic the cells found in the body. AREAS COVERED: In this review, we highlight the current strategies used to maintain stem cell pluripotency (a measure of stem cell quality), as well as provide an overview of the various differentiation strategies being used to generate cells from all three germ lineages. We also discuss the particular considerations that must be addressed when utilizing these cells for translational therapy, and provide an example of a cell type currently used in clinical trials. EXPERT OPINION: The major challenge in regenerative medicine and disease modeling will be in generating functional cells of sufficient quality that are physiologically and epigenetically similar to the diverse cells that they are modeled after. By meeting these criteria, these differentiated products can be successfully used in disease modeling, drug/toxicology screens, and cellular replacement therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.